Framlington Equities global head Mark Hargraves said:
“We would like to thank Dani for his important contribution to Axa IM over the past six years, and we wish him all the best in his future endeavours.
“We have a well-established and highly experienced healthcare team who will continue to ensure we retain a strong platform to maintain the ongoing success and management of our healthcare strategies.”
Saurymper, who has 20 years’ experience in the healthcare sector, joined Axa IM in 2015 from Barclays Capital where he covered European healthcare as a senior equity research analyst.
Before that, he covered global healthcare at Nomura as a sector specialist and spent nine years as senior pharmaceutical analyst at Goldman Sachs, specialising in European pharmaceuticals.
As the country gears up to carry out two million vaccinations a week, you could be forgiven for thinking that investing in healthcare might be a smart move right now.
But while it s true that the extraordinary scientific advances of the last year have rightly made superstars out of women and men in white coats – the likes of Oxford University s Sarah Gilbert and BioNTech founders Ugur Sahin and Ozlem Tureci – it hasn t necessarily given a shot in the arm to those who have bought into big pharmaceutical businesses.
The sector was a standout performer in the first half of 2020, but it underperformed in the second, particularly in the UK.